Ascendis Pharma

Ascendis Pharma is a biopharmaceutical company founded in 2007 that develops therapies on its TransCon technology platform. Its approved products are YUVIWEL (navepegritide) for achondroplasia, SKYTROFA (lonapegsomatropin) for growth hormone deficiency, and YORVIPATH (palopegteriparatide) for hypoparathyroidism.

The company focuses on endocrinology rare disease and oncology, and it collaborates with partners on TransCon-based products in other therapeutic areas. Its stated audiences are patients, caregivers and physicians. Approved medicines are authorized in the United States, the European Union, the EEA and the UK, and are available in several countries including Austria, Germany, France, Italy and Spain. The company also reports that VISEN Pharmaceuticals holds exclusive rights to its endocrinology therapies in Greater China.

Ascendis Pharma is headquartered in Copenhagen, Denmark, with research facilities in Germany and offices across Europe and the United States. It has been listed on Nasdaq (ASND) since its 2015 initial public offering. Current job postings cover clinical development, statistical programming, medical science, research laboratory, IT and HR roles, and the company maintains talent pools in several European countries.

Product: TransCon-based medicines: YUVIWEL (achondroplasia), SKYTROFA (growth hormone deficiency) and YORVIPATH (hypoparathyroidism).